Trial Library is an AI-enabled health technology company that builds tools to increase access to oncology clinical trials by connecting patients, community providers, payers and sponsors with trial opportunities and navigation support[1][2].
High‑Level Overview
- Mission: Expand access to cancer precision medicine by integrating AI-powered navigation and provider activation so clinical trials become a routine care option[1][3].[1][3]
- What it builds / Who it serves: An AI-powered suite (trial search, navigation platform, recruitment/retention and referral optimization) that serves patients, community oncology clinics and healthcare providers, sponsors (biopharma/clinical trial teams) and payers[2][1].[2][1]
- Problem it solves: Low and unequal access to oncology trials—especially in community settings—by automating identification of eligible patients, enabling provider pre‑screening, and offering longitudinal navigation to improve enrollment and retention[2][3].[2][3]
- Growth momentum: Trial Library reports working with 320+ clinics and 1,500+ providers, has raised a $10M Series A to scale its model, and has announced enterprise collaborations (for example with Guardant Health) to broaden trial access[2][3][4].[2][3][4]
Origin Story
- Founding and leadership context: The company was founded and is led by physician‑scientist Hala Borno (CEO/founder), who framed the company from clinical experience seeing the impact of trials and limited access outside academic centers; Trial Library positions itself as bridging care delivery and clinical research[3].[3]
- Early evolution and traction: Trial Library focused on unlocking community‑based access to trials, achieving early network growth (hundreds of clinics/providers), attracting life‑science and payer partnerships, and securing Series A funding to expand its payer and sponsor integrations[2][3].[2][3]
Core Differentiators
- Integrated AI + human navigation: Combines AI‑driven trial matching and compliant patient identification with longitudinal human navigation to drive enrollment and retention—aiming for end‑to‑end support rather than point solutions[1][3].[1][3]
- Community‑first provider network: Emphasis on activating community oncologists (where ~85% of cancer care occurs) with an expanding network (320+ clinics, 1,500+ providers) to reach patients outside academic centers[3][2].[3][2]
- Payer alignment: Claims to be among the first platforms to unlock the payer market for clinical trial access, aligning incentives among payers, providers, patients and life‑science partners to scale adoption and reduce fragmentation[3].[3]
- Sponsor and site solutions: Offers tools for sponsors and trial sites (recruitment/retention, internal referral optimization) and positions itself as an infrastructure partner for biopharma R&D and decentralized trial models[2][1].[2][1]
Role in the Broader Tech & Healthcare Landscape
- Trend alignment: Rides the decentralized clinical trial (DCT) and precision‑medicine trends—demand for decentralized, community‑based recruitment and AI assistance in trial matching has grown as sponsors pursue more representative and faster enrollment[3][2].[3][2]
- Timing and market forces: Increased emphasis on diversity, real‑world evidence, payer cost‑pressure, and digital health adoption create favorable conditions for platforms that can connect community care with clinical research and demonstrate ROI to payers and sponsors[3][4].[3][4]
- Ecosystem influence: By operationalizing provider activation and payer partnerships, Trial Library can shift where and how trials are recruited (moving more activity into community settings) and serve as an interoperability layer between clinics, sponsors and payers[3][4].[3][4]
Quick Take & Future Outlook
- Near term: Expect continued network expansion, deeper payer integrations, and additional sponsor collaborations as Trial Library uses Series A capital to scale navigation and AI capabilities and demonstrate outcomes (enrollment speed, retention, diversity metrics)[3][2][4].[3][2][4]
- Key trends that will shape progress: Regulatory clarity around decentralized trials, payer reimbursement models that value trial access, advances in clinical‑AI explainability, and sponsors’ need for representative enrollment will determine adoption speed[3][4].[3][4]
- Potential impact: If Trial Library continues to grow provider reach and demonstrate measurable improvements in enrollment, retention and equitable access, it could materially accelerate the shift of oncology research into community settings and become a standard operational partner for decentralized oncology trials[3][2][4].[3][2][4]
If you’d like, I can:
- Pull together key metrics and case studies (e.g., the PROMISE Registry example noted on their site) into a one‑page brief[2][2].
- Map Trial Library’s competitors and how its product differentiators compare to other trial‑matching/navigation vendors.
